Apatinib Plus Sox Regimen As Neoadjuvant Chemotherapy For Locally Advanced Gastric Cancer: A Phase Ii Study.

Yanan Zheng,Xiao Yang,Hongpeng Shi,Zhongyin Yang,Chao Yan,Zhentian Ni,Mengjiao Li,Birendra Kumar Sah,Wentao Liu,Wei Xu,Xue-Xin Yao,Zhenglun Zhu,Min Yan,Zhenggang Zhu,Chen Li

DOI: https://doi.org/10.1200/JCO.2018.36.15_suppl.e16014

IF: 45.3

2018-01-01

Journal of Clinical Oncology

Abstract:e16014 Background: Locally advanced gastric cancer (LAGC) occupies a relatively large proportion of gastric cancer and has a low 5-year survival rate. Neoadjuvant chemotherapy is an important part in the treatment of LAGC. We aimed to preliminarily evaluate the efficacy and safety of apatinib, an oral tyrosine kinase inhibitor targeting VEFGR-2, combined with SOX regimen in patients (pts) with LAGC as neoadjuvant chemotherapy. Methods: This is a prospective, single-arm phase II study. LAGC pts with pathologically and/or cytologically confirmed adenocarcinoma were eligible. Prior anti-cancer strategies were not allowed, including radiotherapy, chemotherapy, targeted therapy, and immunotherapy. Pts received 3 cycles (21 days a cycle) of neoadjuvant chemotherapy with apatinib (po, 500 mg qd), S-1 (po, 40-60 mg bid, day1-day14), and oxaliplatin (iv, 130 mg/m2, day1). Apatinib was prohibited in the last cycle. The operation should be performed 4 weeks later of the neoadjuvant chemotherapy. The primary outcome was safety of the neoadjuvant chemotherapy. The secondary outcomes included R0 resection rate, objective response rate (ORR), and disease control rate (DCR). Results: As of 25 January 2018,a total of 20 eligible pts including 15 males and 5 females were recruited. The median age was 60.0 years (range 43-73 years). Poorly differentiated adenocarcinoma was the main histological type (50.0%). All pts completed the neoadjuvant chemotherapy: one pts achieved complete response, 14 had partial response, four had stable disease, and one had progressive disease (PD). The ORR and DCR were 75.0% (15/20) and 95.0% (19/20), respectively. 19 pts received gastric surgery except the one who had PD, and the R0 resection rate was 100%. All pts were included for safety analysis. The incidence of adverse events (AEs) and grade 3/4 AEs were 100.0% and 30.0%, respectively. The most common AEs were hypertension (70.0%), anemia (65.0%), leucopenia (65.0%), and nausea (50.0%). Conclusions: Neoadjuvant chemotherapy with apatinib plus SOX brings clinical benefit to LAGC with a high disease control rate and tolerable adverse reactions. Clinical trial information: ChiCTR-OPC-16010061.